SIAMAB THERAPEUTICS, INC.

617-714-9773

90 Bridge Street Suite 100, Newton, MA 02458

SIAMAB PUBLICATIONS

 

Eavarone DA, Al-Alem L, Lugovskoy A, Prendergast JM, Nazer RI, Stein JN, Dransfield DT, Behrens J, Rueda BR. Humanized anti-Sialyl-Tn antibodies for the treatment of ovarian carcinoma. PLoS ONE. 2018 July; 13(7): e0201314

Starbuck KM, Al-Alem L, Eavarone DA, Hernandez SF, Bellio C, Prendergast JM, Stein J, Dransfield DT, Zarrella B, Growdon WB, Behrens J, Foster R, Rueda BR. Treatment of ovarian cancer by targeting the tumor stem cell-associated carbohydrate antigen, Sialyl-Thomsen-nouveau. Oncotarget, 2018 May; 9:23289-23305.

Prendergast JM, Galvao da Silva AP, Eavarone DA, Ghaderi D, Zhang M, Brady D, Wicks J, DeSander J, Behrens J & Rueda BR. Novel anti-Sialyl-Tn monoclonal antibodies and antibody-drug conjugates demonstrate tumor specificity and anti-tumor activity. mAbs. 2017 Feb; 9(4).

Vered Padler-Karavani, Nancy Hurtado-Ziola, Minya Pu, Hai Yu, Shengshu Huang, Saddam Muthana, Harshal A. Chokhawala, Hongzhi Cao, Patrick Secrest, Dinorah Friedmann-Morvinski, Oded Singer, Darius Ghaderi, Inder M. Verma, Yu-Tsueng Liu, Karen Messer, Xi Chen, Ajit Varki, and Richard Schwab. Human Xeno-Autoantibodies against a Non-Human Sialic Acid Serve as Novel Serum Biomarkers and Immunotherapeutics in Cancer. Cancer Res; 71(9) May 1, 2011.

 

SIAMAB PRESENTATIONS

 

Humanized anti-Sialyl-Tn monoclonal antibody-drug conjugates inhibit tumor growth in vitro and in vivo (AACR-EORTC-NCI 2017)

Novel targeting of tumor infiltrating myeloid derived suppressor cells (MDSCs) through expression of the tumor-specific glycan antigen Sialyl Tn (STn) (Targeting Tumor Myeloid Cells 2017)

Novel anti-Sialyl-Tn monoclonal antibodies and antibody-drug conjugates (ADCs) demonstrate tumor specificity, unique sequence homology and in vitro and in vivo antitumor efficacy (Abstract #LB-221, AACR 2016)

Novel anti-Sialyl-Tn monoclonal antibodies and antibody drug conjugates (ADCs) target a cancer stem cell population and demonstrate in vitro and in vivo anti-tumor efficacy (Society for Glycobiology 2016)

Antibody drug conjugates targeting Sialyl-Tn (STn) demonstrate in vitro and in vivo anti-tumor efficacy (PEGS 2016)

Humanized antibodies targeting tumor-associated Sialyl-Tn (STn) (PEGS 2016)

 

OTHER LITERATURE

 

Büll C, Stoel MA, den Brok MH, Adema GJ. Sialic acids sweeten a tumor's life. Cancer Res. 2014 Jun 15; 74(12); 3199-3204.

Pinho SS, Reis CA. Glycosylation in cancer: mechanisms and clinical implications. Nat Rev Cancer. 2015 Sep; 15(9): 540-55.

Büll C, den Brok MH, Adema GJ. Sweet escape: sialic acids in tumor immune evasion. Biochim Biophys Acta. 2014 Aug; 1846(1): 236-46.

van Kooyk Y, Rabinovich GA. Protein-glycan interactions in the control of innate and adaptive immune responses. Nat Immunol. 2008 Jun; 9(6): 593-601.